Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.

Notwithstanding the high base of last year impacted by Covid-19, steady sales growth, both domestically and in the US, is expected to help drug maker Dr Reddy's Laboratories post a decent topline in the April-June quarter (Q1FY23), said analysts.

The Hyderabad-based company is set to release its Q1FY23 results on Thursday, July 28. As per brokerage estimates, the company is likely to post yearly revenue growth of up to 10 per cent to Rs 5,337 crores.

Net profit, meanwhile, is estimated to rise by 12-37 per cent to Rs 687 crores over last year. Ebitda margins, too, are expected to